Equine Gastric Ulcer Syndrome (EGUS) is extremely prevalent in both racing and non-racing horse populations. The exact aetiology of EGUS is unclear but many stress related risk factors have been implicated including the feeding of grain-based diets. Current treatment techniques often necessitate drug therapy which, when added to feed costs, can be expensive and may have a detrimental effect on digestion due to the mode of action of these therapies. The following experiment set out to investigate if feeding fermented, forage-based feeds (Modified Bio-Fermentation (MBF) lucerne feeds treated with Xanotyde ® , registered as FiberProtect ® and FiberEdge ® ; Fiber Fresh Feeds Ltd, Reporoa, New Zealand), could assist in the healing and prevention of ulceration. Nine adult horses with demonstrable and sustained gastric ulceration (diagnosed by gastric endoscopy), were used in a two part study. The first 42 d healing phase investigated the impact of feeding FiberProtect ® (FPT) or FiberEdge ® (FED) on established gastric ulcers. After 14 d on these diets 44% (4/9) of horses had no ulceration or hyperaemia (inflammation) (EGUC grade 0) and all horses were ulcer free (EGUC grade 0) at d 42. A significant (P < 0.01) relationship was determined between length of time fed and disappearance of ulcers (R 2 = 0.9004; DF = 2). The prevention phase utilised the same horses, ulcer-free at d 42, and fed them a grain-based high energy racing diet alongside FPT at 40% and 60% of the total diet (DM basis). The horses were monitored for a further 28 d (d 42 -d 70), and only three showed a recurrence of ulceration throughout this period. At d 70, eight out of nine horses were ulcer free (EGUC grade 0). The findings suggest that FPT and FED can be used to heal and prevent gastric ulceration, and that FPT can be fed alongside a high grain diet to prevent recurrence of gastric ulcers.
An 8‐year‐old, spayed, female miniature poodle was presented to the University of Pennsylvania Veterinary Hospital (UPVH) with signs of mild respiratory distress related to increasing laryngeal obstruction. The dog was found to have a unicentric mast cell sarcoma involving the larynx, with tumour infiltration of the tissues between the thyroid and arytenoid cartilages as well as subglottic narrowing. Treatment and differential diagnosis are described.
9515 Background: The definition of histopathologic high-risk features (HRF) in enucleated eyes of children with unilateral retinoblastoma and their contribution to metastases is controversial. The COG completed a large, prospective international study to determine the prevalence of strictly defined histopathologic HRF that are predictors of recurrence and the role of chemotherapy to prevent recurrences. Methods: All patients who underwent enucleation for unilateral retinoblastoma were eligible for the study. Pathology slides were submitted for central review within 21 days of enucleation. Patients with evidence of one or more high-risk features (posterior uveal invasion grades IIC and D, concurrent optic nerve and choroid involvement and post-lamina optic nerve involvement) as determined by central review, received 6 cycles of chemotherapy consisting of carboplatin, vincristine and etoposide. All others were observed. All patients were followed for extraocular recurrences. Results: Patients were enrolled from February of 2005 until May 2010. As of July 2011, the median follow-up from enrollment was 1.9 years (max=5.3 years). Of 312 patients with central histopathology review, 49 patients had their risk classification changed (13% with no HRF had HRF, 24% with HRF had no HRF). Two patients developed extraocular disease and one patient died of unknown cause. The death and one of the extraocular relapses occurred among the 93 (2/93=2.2%, upper 95% CI 3.4%) patients assigned by the central review to receive chemotherapy, while one patient experienced extraocular relapse among the 209 (1/209=0.5%, upper 95% CI 0.6%) assigned to observation only. There is no evidence of a difference in the EFS and OS in these two groups. Conclusions: Preliminary results strongly suggest that a central review of pathology can spare a significant number of patients from exposure to chemotherapy. Chemotherapy may have contributed to fewer relapses in patients with high-risk features as defined in this study. The preliminary results from this study indicate an excellent outcome with this approach.
SummaryCalcium is considered important in buffering excess stomach acid in mammals, including horses. Control of stomach acid is important in preventing the development of ulcers within the stomach lining, which, in horses, are considered to be caused by acid splashing. Algae supplements contain various minerals which are in natural form, as seen in all plant and feedstuffs. The current trial was conducted to examine if a high calcium algae supplement had any impact on gastric ulceration in horses, which may be due to buffering stomach acid, reducing the pH in a gradual manner, without resorting to medication. Ten horses, of either thoroughbred, standardbred or sport horse breed, were selected on the basis of the presence of ulcers in their stomach, as ascertained by endoscopy. The average ulceration score before algae supplementation was 2.2 ± 0.75 according to the EGUC scoring system. The horses were then maintained on their normal diet (unchanged from the initial ulcer scoring) by the owner with the addition of 40 g per day of the high calcium, algae based Maxia Complete® (Seahorse Supplements Ltd, Christchurch, NZ) for thirty days (T30). All horses were then re endoscoped to assess any change in ulceration score. All horses showed a significant improvement in ulcer score, with seven having a score of zero (fully healed, no evidence of further ulceration) and two with a score of one (some residual inflammation or keratinosis in areas of healed ulcers). This resulted in a mean score of 0.3 ± 0.48 (P < 0.0001: T0 versus T30) at the end of the study. This trial demonstrated that feeding an organic form of high calcium from algae reduced ulceration in horses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.